Nexalin Technology (NXL) Total Debt (2021)

Nexalin Technology (NXL) recorded quarterly Total Debt of $60116.0 in Q4 2021.

Nexalin Technology (NXL) Total Debt (2021) Analysis & Trends

Nexalin Technology's Total Debt history runs 1 years deep, the most recent figure standing at $60116.0 for Q4 2021.

In Q4 2021, Total Debt changed N/A year-over-year to $60116.0; the TTM figure through Dec 2021 stood at $60116.0 (changed N/A YoY), while the FY2021 annual figure was $60116.0, changed N/A from the prior year.
Total Debt was $60116.0 for Q4 2021 at Nexalin Technology.
In the past five years, Total Debt ranged from a high of $60116.0 in Q4 2021 to a low of $60116.0 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	34.05 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	14.72 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	28.07 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	11.03 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	598.50 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	9.48 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	10.13 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	1.93 Bn
10	Nexalin Technology	7.82 Mn	5.11 Mn	13,133.00	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	60,116.00